EA
EIGR

Elm Advisors’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Elm Advisors’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-105
Closed -$39K – 269
2020
Q4 		$39K Buy
+105
New +$30.1K 0.02% 176

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Elm Advisors's EIGR Position: Q1 2021 in Review

Elm Advisors sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q1 2021, closing a stake of 105 shares — an estimated $39K sold.

Elm Advisors first reported a position in EIGR in Q4 2020 and held it in 1 quarter. The position peaked at $39K in Q4 2020. 94 funds tracked by Wall St. Rank hold EIGR as of Q1 2021.

  • Elm Advisors reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Elm Advisors sold 105 Eiger BioPharmaceuticals, Inc. shares in Q1 2021, an estimated $39K.
  • Elm Advisors first reported a position in Eiger BioPharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Elm Advisors's Eiger BioPharmaceuticals, Inc. position peaked at $39K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q1 2021.

Based on Elm Advisors's 13F filing for Q1 2021, filed 5 Apr 2021.